Epicatechin
Epicatechin (cocoa flavan-3-ol)
Written by Aaron CuhaReviewed Sep 2026
Also known as: (-)-Epicatechin, Epi, EPI, Flavan-3-ol, (+)-Epicatechin (synthetic enantiomer, Epirium Bio)
Extended median lifespan of male mice by 5 percent in the 2021 Interventions Testing Program cohort, with no effect in females. In people, small randomised trials of the pure compound show an insulin signal at 100 mg a day and nothing at 25 mg a day, and the endothelial effect that made its name is best documented as an acute response to cocoa.
Overview
Epicatechin is the flavan-3-ol that gives cocoa most of its vascular reputation. It is sold as a purified supplement, mostly on the strength of a 2014 report that a week of it raised grip strength and the follistatin to myostatin ratio in a handful of people, and it is the compound in cocoa that the 2006 PNAS mechanistic study identified as responsible for the acute improvement in flow-mediated dilation after a flavanol-rich drink.
The randomised human record for the pure compound is small and mixed. In 37 adults aged 40 to 80 with untreated high-normal blood pressure, 100 mg a day for four weeks did not significantly change flow-mediated dilation (1.1 percentage points, 95 percent CI -0.1 to 2.3, p = 0.07) or blood pressure, but did lower fasting insulin by 1.46 mU/L and HOMA-IR by 0.38. In 48 overweight or obese adults with features of metabolic syndrome, 25 mg a day for two weeks changed nothing: not blood pressure, glucose, insulin, lipids or oxidised LDL. A 2022 systematic review of 11 randomised trials found that apart from a dose-dependent acute rise in flow-mediated dilation in healthy young adults, effects of epicatechin itself were not observed, and rated most trials as carrying some risk of bias.
In mice, the NIA Interventions Testing Program fed epicatechin from 7 months of age. Males lived longer: median 836 against 794 days, a 5.3 percent increase (log-rank p = 0.037), and survival to the 90th percentile age rose 6.2 percent (Wang-Allison p = 0.01), with the trend present at all three sites. Females showed nothing (median -2.2 percent, p = 0.6). The paper's main text does not state the diet concentration; it is in the supplementary tables.
Epicatechin is a food constituent and a dietary supplement. It is not an approved drug anywhere. A synthetic (+)-epicatechin enantiomer has been taken through a 22-person phase 1 in Becker muscular dystrophy and a 10-person open-label phase 2 in Friedreich ataxia by a small company, which is a different molecule from the (-)-epicatechin in cocoa and in most supplements.
Mechanism of action
In people, ingestion of flavanol-rich cocoa acutely raises circulating nitric oxide species and flow-mediated dilation, and regression analysis identified (-)-epicatechin and its 7-O-glucuronide metabolite as the independent predictors of that effect; giving pure (-)-epicatechin reproduced it, and blocking nitric oxide synthase abolished it. In seven adults with Becker muscular dystrophy, eight weeks of 50 mg twice daily raised muscle LKB1, AMPK and PGC-1alpha, increased mitochondrial cristae density on electron microscopy, and shifted follistatin up and myostatin down, in an open-label study with no control group. In rodents, epicatechin increases angiogenic and mitochondrial signalling in skeletal muscle and improves treadmill performance. The ITP selected it on that basis. Why the lifespan effect appeared only in males is not known; the same male bias runs through most ITP positives and is unexplained.
Human evidence
Real but small. Pure epicatechin has been given to people in roughly a dozen randomised trials, all short (days to four weeks) and none larger than about 50 participants, plus open-label muscle studies of seven or fewer people. Cocoa trials are much larger but cannot isolate epicatechin.
- 37 adults aged 40 to 80 with high-normal blood pressure, 100 mg a day for 4 weeks, crossover: flow-mediated dilation not significantly changed (p = 0.07); fasting insulin -1.46 mU/L and HOMA-IR -0.38, both significant; no change in blood pressure or lipids.
- 48 overweight or obese adults, 25 mg a day for 2 weeks, crossover: no effect on any cardiometabolic measure.
- Systematic review of 11 randomised trials: only an acute flow-mediated dilation rise in healthy young adults was consistently observed.
- Meta-regression of 16 cocoa trials estimated that 25 mg a day of epicatechin ingested as cocoa is associated with about 4 mmHg lower systolic pressure, but this is cocoa, not the pure compound, and the pure compound at that dose did nothing in the 48-person trial.
- Muscle: a 7-day proof of concept reported higher grip strength and follistatin to myostatin ratio; 7 adults with Becker muscular dystrophy on 50 mg twice daily for 8 weeks showed mitochondrial and regeneration markers moving, without a control group.
- No human study has measured any ageing endpoint, and none has run longer than a few months.
What this does not tell you: Nothing here shows that epicatechin changes how long or how well a person lives. The one consistent human finding is an acute vascular response; the insulin finding comes from a single 37-person crossover and was not reproduced at a lower dose. The muscle claims rest on seven or fewer people without controls. The mouse lifespan result is in males only and the human trials have not tested sex as a variable.
Reading the research record
The NIA Interventions Testing Program runs each compound in parallel at three sites (The Jackson Laboratory, the University of Michigan and UT Health San Antonio) in genetically heterogeneous UM-HET3 mice, tests both sexes, analyses them separately, pools the sites in a site-stratified log-rank test, and publishes every result whether or not the compound worked. It is publicly funded by the National Institute on Aging with no pharmaceutical sponsorship. In the 2021 cohort epicatechin extended male median lifespan by 5.3 percent (p = 0.037) and 90th percentile survival by 6.2 percent (p = 0.01), trending the same way at all three sites, and did nothing in females. That is a modest but real result in the programme built to catch results that do not replicate. It has been tested once, at one dose, from one starting age; the ITP has repeatedly found that positives at one dose or age do not hold at another (astaxanthin, meclizine and mitoglitazone all failed retests in the 2022 cohort), so this should be read as a first result rather than a confirmed one.
The human record is thin for the usual economic reason and one more. Epicatechin cannot be patented, so there is no sponsor for a large trial, and the food-industry money that does exist has gone into cocoa products rather than the pure compound, which is why the big trials cannot attribute their effects to epicatechin. Without trials, both benefit and harm go unmeasured. The 2022 systematic review's conclusion, that it is unclear whether epicatechin has no effect on most endpoints or whether the trials were too small to detect one, is the honest state of the record.
The evidence, charted
Fig. 1 · evidence composition
6of 8 citations (75%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 7 distinct years, 2006 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Animal2026
Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice
Interventions Testing Program 2021 cohort, treatment from 7 months. Male median lifespan 836 versus 794 days (+5.3 percent, log-rank p = 0.037), 90th percentile survival +6.2 percent (p = 0.01); 141 treated males against 298 controls. Females: median -2.2 percent, p = 0.6. NIA funded.
GeroScience - Human2015
Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial
37 adults aged 40 to 80 with systolic pressure 125 to 160 mmHg, 100 mg (-)-epicatechin a day for 4 weeks in crossover. Flow-mediated dilation: +1.1 percentage points, 95 percent CI -0.1 to 2.3, p = 0.07, not significant. Fasting insulin fell 1.46 mU/L (p = 0.03) and HOMA-IR fell 0.38 (p = 0.04). No change in blood pressure, arterial stiffness or lipids. Funding not stated in the abstract retrieved.
American Journal of Clinical Nutrition - Human2018
A nutritive dose of pure (-)-epicatechin does not beneficially affect increased cardiometabolic risk factors in overweight-to-obese adults: a randomized, placebo-controlled, double-blind crossover study
48 overweight or obese non-smokers aged 20 to 65 with features of metabolic syndrome, 25 mg (-)-epicatechin a day for 2 weeks in crossover. No significant effect on blood pressure, glucose, insulin, HOMA-IR, triglycerides, total, LDL or HDL cholesterol, or oxidised LDL. The authors conclude the cocoa effect cannot be ascribed to epicatechin alone.
American Journal of Clinical Nutrition - Review2022
Effect of an (-)-epicatechin intake on cardiometabolic parameters: a systematic review of randomized controlled trials
11 randomised trials of epicatechin itself. Apart from a dose-dependent acute increase in flow-mediated dilation and peripheral arterial tonometry in healthy young adults, no effects were observed on vascular, glucose, lipid, oxidative stress, inflammation, appetite or body weight endpoints. Most trials rated as having some risk of bias.
Nutrients - Human2006
(-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans
In healthy men, flavanol-rich cocoa acutely raised circulating nitric oxide species and flow-mediated dilation; (-)-epicatechin and its 7-O-glucuronide were the independent predictors, pure (-)-epicatechin reproduced the effect, and nitric oxide synthase inhibition abolished it. The mechanistic paper behind the supplement's reputation.
Proceedings of the National Academy of Sciences - Human2014
Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation
Mouse data plus an initial proof-of-concept in humans: 7 days of (-)-epicatechin increased hand grip strength and the plasma follistatin to myostatin ratio. Small, uncontrolled and short; this is the study most supplement marketing traces back to.
Journal of Nutritional Biochemistry - Human2021
(-)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy
Open-label, 7 ambulatory adults, 50 mg twice daily for 8 weeks with biceps biopsy before and after. Increased LKB1, AMPK, PGC-1alpha, cristae abundance, follistatin and regeneration markers; myostatin fell; heart rate and lactate at fixed workloads fell. No placebo group.
Muscle and Nerve - Human2022
Safety and biomarker response to (+)-epicatechin in Becker muscular dystrophy
Phase 1 open-label dose escalation of the synthetic (+) enantiomer in 22 participants, sponsored by Epirium Bio, completed March 2022. No results posted on the registry at the time of review.
ClinicalTrials.gov
Frequently asked questions
Did epicatechin extend lifespan in the ITP?
In male mice, yes: median lifespan rose 5.3 percent (836 versus 794 days, p = 0.037) and survival to the 90th percentile age rose 6.2 percent when feeding began at 7 months. In female mice it did nothing. It has been tested once, and other ITP positives have failed when retested at a different dose or start age.
Does epicatechin improve blood vessel function in people?
Acutely, after a cocoa drink or a single pure dose, flow-mediated dilation rises, and that is well documented in healthy young adults. Over four weeks of 100 mg a day in 37 middle-aged adults, the change in flow-mediated dilation was 1.1 percentage points with a confidence interval crossing zero. Blood pressure did not change in either pure-compound trial.
Does it build muscle or lower myostatin?
A 7-day proof-of-concept study reported higher grip strength and a higher follistatin to myostatin ratio, and an 8-week open-label study in 7 adults with Becker muscular dystrophy reported the same direction with muscle biopsy changes. Neither had a placebo group and neither measured muscle mass. No controlled trial has tested this claim.
What dose was used in the human trials?
25 mg a day (no effect in 48 overweight adults over 2 weeks) and 100 mg a day (insulin lowered, flow-mediated dilation not significantly changed, in 37 adults over 4 weeks). The muscular dystrophy study used 50 mg twice daily. No trial has run longer than a few months.